Attorney Advertising
FMC (FMC) Securities Class Action: Distributor Inventory, 2026 Guidance and January 19, 2027 Deadline
By W. Scott Holleman, Partner · Julie & Holleman LLP
Published November 20, 2026
A federal securities class action, Godeas v. FMC Corporation, alleges that FMC (NYSE: FMC) — a global crop-protection and agricultural-sciences company — and executives Pierre R. Brondeau and Andrew D. Sandifer misled investors about the company's 2026 outlook and the severity of inventory problems at the distributors that buy and resell FMC products. The proposed class period runs February 4 – October 14, 2026, with a lead-plaintiff deadline of January 19, 2027. The allegations have not been proven.
A federal securities class action has been filed against FMC Corporation (NYSE: FMC) — a global agricultural-sciences and crop-protection company — and senior executives Pierre R. Brondeau and Andrew D. Sandifer. The complaint alleges that investors were misled about FMC's 2026 financial outlook and the severity of inventory problems affecting the distributors that purchase and resell FMC products: the company had been signaling confidence in volume growth, new product launches, cost reductions, and its post-patent strategy while distribution-channel customers held higher-priced inventory that was increasingly difficult to sell at prevailing market prices.
The case is Godeas v. FMC Corporation, et al., No. 2:26-cv-08831, in the U.S. District Court for the Eastern District of Pennsylvania. The currently pleaded class period is February 4 through October 14, 2026, inclusive, and the complaint asserts claims under Section 10(b) and Section 20(a) of the Securities Exchange Act and SEC Rule 10b-5 — the core provisions of any securities class action. Published notices identify January 19, 2027 as the deadline to move for appointment as lead plaintiff.
This litigation is at the allegation stage: the complaint has not established that FMC or either executive committed securities fraud, and filing a lawsuit does not mean a court has found any fact proved. Julie & Holleman LLP did not file this action and is not counsel of record for the Godeas complaint; the firm is independently reviewing the allegations and the rights of investors and continuing stockholders.
- Case Details
- Case
- Godeas v. FMC Corporation, et al.
- Court
- U.S. District Court, Eastern District of Pennsylvania
- Case No.
- 2:26-cv-08831
- Class Period
- February 4 – October 14, 2026
- Lead Plaintiff Deadline
- January 19, 2027
What Does the FMC Securities Complaint Allege?
The complaint centers on FMC's distributor-inventory challenge. FMC sells crop-protection products through distribution channels, and those distributors in turn sell to growers. During a market downturn, some distributors retained products acquired at relatively high prices; as competing products — especially generics following the expiration of certain intellectual-property protections — became less expensive, selling the older, higher-priced products became more difficult. Distributors sought to operate with lower inventory balances, and their reduced replenishment purchases constrained FMC's sales and cash-generation prospects. This concerns inventory held by distribution-channel customers, not FMC's own on-balance-sheet manufacturing inventory, and the complaint does not establish any proven “channel-stuffing” scheme.
The plaintiff alleges management knew or recklessly disregarded the seriousness of this problem yet issued misleadingly optimistic statements about its 2026 forecasts. The challenged subjects include the Rynaxypyr post-patent strategy, generic competition, manufacturing-cost reductions, new active ingredients, branded product sales, distributor orders, revenue, adjusted EBITDA, and free cash flow.
The legal question is not simply whether a forecast later proved wrong. It is whether particular public statements were materially misleading when made, in light of information then known or recklessly disregarded, and whether the alleged misstatements caused compensable investor losses.
What Guidance Did FMC Give Investors in February and July 2026?
On February 4, 2026, FMC projected approximately $3.60 billion to $3.80 billion in full-year 2026 revenue and $670 million to $730 million in adjusted EBITDA. The company acknowledged competitive pricing pressure — including the evolving market for Rynaxypyr after patent protection — while describing steps to make its legacy portfolio more cost-competitive, along with cost-cutting initiatives, new products, strategic transactions, and efforts to strengthen its balance sheet.
FMC maintained its full-year guidance after reporting first-quarter results in April. On July 29, 2026, after second-quarter results, it lowered its full-year outlook to $3.50 billion to $3.70 billion in revenue and $620 million to $680 million in adjusted EBITDA, citing softer demand for legacy products, lower orders from diamide partners, and competitive pressure while continuing to discuss longer-term improvement. These projections were management's expectations at the time — not guarantees, and not proof by themselves of the complaint's allegations.
What Happened on October 15, 2026?
Before trading on October 15, 2026, FMC issued a substantial preliminary update about its third-quarter outlook. It expected third-quarter revenue of $65 million to $125 million and third-quarter adjusted EBITDA of negative $565 million to negative $510 million. Those estimates included an anticipated $625 million to $675 million impact from comprehensive commercial measures to address selected higher-priced products already held by channel customers and to change pricing and rebate mechanics in the United States.
FMC explained that higher-priced inventory held at some distribution customers, weak demand, generic competition, and an increasing gap between inventory values and current market prices had impeded sales to growers and replenishment purchases. The company announced measures affecting Brazil, Argentina, the United States, and Canada, along with a proposed change to its U.S. high-gross-price / high-rebate structure. Those are the company's public disclosures; the plaintiff's separate allegation is that the seriousness of the problem should have been conveyed earlier.
The publication date matters: the company's announcement is dated October 15, not October 14. October 14 was the last trading day before the disclosed results. Although parts of the complaint refer to an October 14 disclosure, FMC's own release and SEC Form 8-K establish October 15 as the correct public announcement date.
How Much Did FMC Shares Decline?
The complaint reports that FMC shares closed at $8.09 on October 14 and $5.62 on October 15, 2026 — a $2.47 per-share decline, approximately 30.5%. The plaintiff alleges that the stock-price reaction reflected the market learning previously concealed adverse information.
The size of the decline alone does not determine whether an actionable misstatement occurred or what damages, if any, an investor may legally recover. Individual transactions and market- or company-specific factors will matter, and loss causation is assessed separately from the full observed trading decline.
What Did FMC Report on October 29, 2026?
FMC subsequently announced actual third-quarter results on October 29, 2026, reporting approximately $106 million in quarterly revenue, including a $639 million negative revenue effect from the commercial actions announced on October 15. The company also stated that, excluding India and the commercial actions, third-quarter revenue was approximately $745 million, and it described weaker demand and significantly lower channel replenishment as additional pressures.
FMC also reduced its full-year 2026 outlook to revenue of $2.75 billion to $2.85 billion and adjusted EBITDA of negative $124 million to negative $104 million. These are not the same as the preliminary third-quarter ranges disclosed on October 15 — they are subsequent company disclosures, occurring after the presently pleaded October 14 class-period ending date. The October 15 figures were an estimated impact; the October 29 figures are reported results. These later announcements may provide context for the allegations, but they should not be mislabeled as events occurring inside the proposed purchase period.
What Federal Securities Claims Are Asserted?
The plaintiff asserts claims under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, alleging material misrepresentations or omissions in public communications, together with Section 20(a) claims addressing the potential responsibility of controlling persons, including the named executives.
Issues to be litigated can include whether the statements were actionable rather than protected forecasts, materiality, scienter, reliance, loss causation, damages, and relevant defenses. The plaintiff's allegations are not SEC findings; the complaint does not establish that FMC restated its financial statements or that its directors breached fiduciary duties.
Which FMC Investors May Be Affected?
The complaint proposes to represent investors who purchased or otherwise acquired FMC common stock between February 4 and October 14, 2026, inclusive, and suffered legally cognizable losses. Whether any particular investor has a viable claim depends on transaction records, acquisition and sale dates, individual circumstances, the evolving pleading, loss causation, and eventual judicial rulings. A purchase made only on October 15 is not within the currently alleged purchase period, although counsel should assess any investor's actual situation and monitor amendments.
Investors should preserve confirmations and brokerage statements showing all FMC purchases, sales, transfers, and corporate actions, together with any existing loss calculations. A person who later sold shares is not necessarily barred from all federal securities remedies merely because of the sale, but standing and damages require legal assessment. There is no need to send account credentials or confidential brokerage data through a public web form.
What Is the January 19, 2027 Lead Plaintiff Deadline?
Public PSLRA notices for this newly filed action identify January 19, 2027 as the last day for an investor to seek appointment by the court as lead plaintiff. A lead plaintiff, if appointed, can represent the proposed class and oversee litigation counsel under the relevant procedural framework.
Do I Have to File by That Date?
This date is not ordinarily a requirement that every prospective absent class member submit a motion or opt into the lawsuit. Separate claim-submission procedures could arise only if a settlement or other court-approved process occurs later.
Should I Confirm the Current Status?
Investors considering a leadership role should promptly seek case-specific legal advice, preserve all relevant records, and confirm the case's procedural status. A later filing or consolidation can affect the issues and class definition even when the publicized motion deadline remains unchanged, and no firm can guarantee appointment or a recovery.
May Continuing FMC Stockholders Have Separate Derivative Rights?
FMC is incorporated in Delaware, notwithstanding a contrary statement in the filed complaint. A stockholder-derivative action is distinct from an investor's personal federal securities claim: in a potential derivative case, a stockholder may — if stringent standing and procedural requirements are satisfied — pursue a claim belonging to the corporation, rather than seek compensation simply for an individual decline in stock value. Whether there was injury to FMC, an actionable breach of fiduciary duty, an adequate board process, or a basis to pursue corporate records are independent questions.
Topics counsel may examine include how management and directors monitored distributor inventory and forecast risks; the timing and completeness of board-level information; the company's disclosure and risk-management controls; the rationale, authorization, and process for the large commercial repricing actions; and any legally cognizable corporate harm. Depending on the facts and standing, Delaware General Corporation Law Section 220 may provide a path to request certain books and records, subject to requirements and statutory limitations (including amendments effective in 2025). Derivative litigation also raises contemporaneous and continuing ownership issues and board-demand / demand-futility requirements. No derivative claim is established by this securities complaint, and there is no assertion here that J&H has filed one — a decline in the price of FMC stock is not itself corporate harm sufficient for a derivative suit.
Contact Julie & Holleman LLP About FMC Investor or Stockholder Rights
Julie & Holleman LLP reviews significant public-company securities and corporate-governance matters, and welcomes inquiries from two groups — some investors may fall into both:
Investors With Securities Losses
Investors who purchased FMC shares during the proposed February 4 – October 14, 2026 class period and wish to discuss potential federal securities rights, including the January 19, 2027 lead-plaintiff process.
Continuing FMC Stockholders
Continuing holders interested in a separate, preliminary evaluation of possible Delaware corporate-governance or derivative rights, which involve different legal requirements and are assessed separately. Contact does not create an attorney-client relationship, and there is no need to send passwords or confidential documents through an initial form.
Frequently Asked Questions — FMC (NYSE: FMC)
- What is the FMC securities class action about?
- It concerns alleged misleading statements about FMC's 2026 financial outlook and distributor-held inventory that limited sales of crop-protection products and subsequent replenishment orders. The allegations have not been proved, and Julie & Holleman LLP did not file the case and is not counsel of record.
- What dates are covered by the complaint?
- February 4 through October 14, 2026, inclusive, under the complaint as initially filed.
- When is the FMC lead-plaintiff deadline?
- January 19, 2027, according to published PSLRA notices, subject to current docket verification. This is a motion deadline for would-be lead plaintiffs, not a universal investor registration deadline.
- Did FMC announce the third-quarter warning on October 14 or October 15?
- The issuer's release and SEC Form 8-K are dated October 15, 2026. October 14 is the pre-disclosure closing-price date used as the comparison, not the news-release date.
- What did the company say about inventory?
- FMC said selected higher-priced products already held by distributors were difficult to move at then-prevailing market prices, depressing replenishment demand and prompting commercial actions. This is distribution-channel inventory, not FMC's own warehouse stock.
- How far did FMC shares fall following the October 15 announcement?
- The complaint describes a decline from $8.09 to $5.62, approximately 30.5%, between the October 14 and October 15 closing prices. A price decline alone does not establish fraud or recoverable damages.
- Is FMC a Pennsylvania corporation?
- No. FMC's SEC filings identify it as a Delaware corporation, with executive headquarters in Philadelphia, Pennsylvania. The initiating complaint contains an inconsistent description, which does not change the company's actual incorporation.
- Are a securities class action and a stockholder derivative lawsuit the same?
- No. The securities action concerns alleged personal trading losses arising from statements to the market. Derivative litigation, if legally available, generally asserts a claim belonging to the corporation.
- Must I still own FMC stock to ask about the securities class action?
- Not necessarily. Counsel should review your actual acquisition and sale dates and economic losses. Ownership and standing may differ for a potential derivative claim.
- Does filing this lawsuit establish fraud or a settlement?
- No. The complaint contains allegations, and no recovery, certification, judicial finding, or settlement is established by the filing alone.
Related guides
Contact
W. Scott Holleman, Partner
Julie & Holleman LLP
Scott focuses his practice on stockholder litigation involving federal securities laws, corporate governance, mergers and acquisitions, and other public-company disputes.
Prior results do not guarantee a similar outcome.
Disclaimer: This page describes allegations in a newly filed, contested complaint and publicly disclosed events, attributing allegations to the complaint and financial figures and dates to FMC's SEC filings and releases. FMC is a Delaware corporation headquartered in Philadelphia (the complaint's contrary description is inaccurate), and the corrective disclosure was announced October 15, 2026 (October 14 is only the prior closing-price date). The February, July, October 15 preliminary, and October 29 actual figures are distinct periods and bases, some excluding India; adjusted EBITDA is not GAAP net income, and a revenue impact is not a cash outflow. The securities action was brought by other counsel; Julie & Holleman LLP is not counsel of record. No liability, restatement, SEC finding, insider trading, or derivative claim is established, and the roughly 30.5% stock move is not an adjudicated measure of damages. This page is general information, not legal advice.
